Supplementary Material

Baseline Assessment:

Correlations

Pearson's correlation test was used to identify CMR derived RV mass and volume variables that had a significant correlation with mPAP, PVR, mixed venous oxygen saturation (SvO2), RVEF_{%pred} and RA area (**Supplementary Table 2**).

Significant correlations were observed between mPAP with all RV mass and volume variables, VMI had the strongest correlation (r=0.525, p<0.001). PVR was significantly correlated with RVEF_{%pred} (r=-0.467, p<0.001), RVEDVI_{%pred}/VMI (r=-0.400, p<0.001), RVESVI_{%pred}/VMI (r=-0.197, p<0.001) and VMI (r= 0.465, p<0.001). Variables that correlated with SvO2 included RVEDVI_{%pred} (r= -0.212, p<0.001), RVESVI_{%pred} (r= -0.325, p<0.001), RVEF_{%pred} (r=0.404, p<0.001), RVEDVI_{%pred}/VMI (r=0.189, p<0.001), VMI (r= -0.257, p<0.001) and RA area (r= -0.300, p<0.001).

Survival analyses

Cox regression model with an enter approach involves using all the selected variables in the derivation of the model.

Follow-up Assessment:

Transition of RV volume and mass parameters: Independent t-test

Independent unpaired t-test was used to compare the values of RVESVI%pred and VMI in the alive and dead cohorts.

Among patients who survived, significant reduction was observed in mean RVESVI_{%pred} (from 212.6±122.0 to 170.0±81.3; p=0.012) and VMI (from 0.58±0.34 to 0.46±0.23; p=0.012). In contrast, there was no significant change in mean RVESVI_{%pred} or VMI for patients who died.

Survival Analyses

Cox regression model with a forward approach starts with an empty model and adds in variables one by one, while prioritising variable that gives the single best improvement.

Supplementary Table 1: Treatment regimen in incident and prevalent patients

Treatment Regimen	Incident (N=362)	Prevalent (N=142)
Monotherapy	121 (33.4%)	22 (15.5)
Combination therapy	183 (50.6%)	82 (57.7%)
lloprost	53 (14.6%)	38 (26.8)
Not on treatment	5 (1.4%)	0 (0.0%)

Supplementary Table 2: Pearson Correlations of the variables

	mPAP		PVR		SvO ₂	
Variable	r Value	p-value	r Value	p-value	r Value	p-value
RVEDVI _{%pred}	0.261	<0.001	0.186	<0.001	-0.212	<0.001
RVESVI%pred	0.319	<0.001	0.326	<0.001	-0.325	<0.001
RVEF%pred	-0.393	<0.001	-0.467	<0.001	0.404	<0.001
RVEDVI _{%pred} /VMI	-0.413	<0.001	-0.400	<0.001	0.189	<0.001
RVESVI%pred/VMI	-0.248	<0.001	-0.197	<0.001	0.001	0.984
VMI	0.525	<0.001	0.465	<0.001	-0.257	<0.001
RA Area	0.262	<0.001	0.197	<0.001	-0.300	<0.001

upplementary Table 3: Bivariate Model of RVESVI%pred and VMI
--

	В	SE	Wald	df	p-value	Hazard Ratio	95% CI Lower Limit	95% CI Upper Limit
RVESVI _{%pred}	0.002	0.001	12.834	1	<0.001	1.002	1.001	1.003
VMI	-0.965	0.270	11.939	1	0.001	0.381	0.220	0.659

Heart

Supplementary Table 4: Demographics and comparison of different volume/mass groups at follow-up

	All Groups	LVLM	LVHM (N=15)	HVLM (N=23)	HVHM (N=24)
	(11-124)	(11-02)	(14-13)	(11-23)	(11-2+)
Demographics					
Age (years)	53 (16)	53 [†] (15)	42§ (11)	67 ^{†§¶} (12)	48¶ (16)
Sex M/F (n, male %)	35/89 (28%)	19/43 (31%)	4/11 (27%)	7/16 (30%)	5/19 (21%)
PAH subtype (n, %)					
IPAH	64 (51.6%)	33 (53.2%)	9 (60.0%)	6 [¶] (26.1%)	16 [¶] (66.7%)
PAH-CTD	48 (38.7%)	22 (35.5%)	5 (33.3%)	15 [¶] (65.2%)	6¶ (25.0%)
Other Subtypes	12 (9.7%)	7 (11.3%)	1 (6.7%)	2 (8.7%)	2 (8.3%)
Treatment regimen (n, %)					
Monotherapy	23 (19.2%)	15 (25.9%)	3 (20.0%)	3 (13.0%)	2 (8.3%)
Combination	59 (49.2%)	31 (53.4%)	6 (40.0%)	11 (47.8%)	11 (45.8%)
lloprost	38 (31.7%)	12 (20.7%)	6 (40.0%)	9 (39.1%)	11 (45.8%)

Treatment data is not available for 4 patients.

••	-			0 1	•	0		
	В	SE	Wald	df	p-value	Hazard Ratio	95% CI Lower Limit	95% CI Upper Limit
Age at Follow-up	0.042	0.012	12.452	1	<0.001	1.042	1.019	1.067
LVLM			16.367	3	0.001			
LVHM	1.460	0.495	8.689	1	0.003	4.305	1.631	11.362
HVLM	1.193	0.397	9.046	1	0.003	3.298	1.515	7.176
HVHM	1.377	0.407	11.464	1	0.001	3.965	1.786	8.800

Supplementary Table 5: Multivariable Model of Volume/Mass group at follow-up and Age